Share This Page
Drugs in ATC Class M04AC
✉ Email this page to a colleague
Drugs in ATC Class: M04AC - Preparations with no effect on uric acid metabolism
| Tradename | Generic Name |
|---|---|
| COLCHICINE | colchicine |
| MITIGARE | colchicine |
| GLOPERBA | colchicine |
| >Tradename | >Generic Name |
Market Dynamics and Patent Landscape for ATC Class M04AC – Preparations with No Effect on Uric Acid Metabolism
What Are the Key Market Trends in M04AC?
The ATC code M04AC covers preparations primarily aimed at treating gout and hyperuricemia without directly affecting uric acid metabolism. This subgroup includes anti-inflammatory agents and uric acid excretion modulators that do not alter uric acid levels directly. The market for these drugs reflects shifting therapeutic approaches, regulatory pressures, and patent activity.
Market Size and Growth:
Global sales of non-uric acid affecting gout treatments exceeded $2.5 billion in 2022. The compound annual growth rate (CAGR) from 2018 to 2022 approximated 4%. Factors propelling this growth include increased incidence of gout, rising awareness about gout management, and the approval of new formulations.
Key Market Drivers:
- Growing prevalence of gout linked to obesity, aging populations, and diet.
- Demand for alternative therapies due to side effects of traditional uric acid lowering agents (e.g., allopurinol).
- Advances in anti-inflammatory drugs that do not impact uric acid levels, such as IL-1 inhibitors.
Market Challenges:
- Competition from established drugs like colchicine and corticosteroids.
- Patent expirations of major drugs, reducing exclusivity and maintaining price pressure.
- Regulatory hurdles in demonstrating safety and efficacy for new patients.
Who Are the Major Players in the M04AC Patent Landscape?
Patent filings predominantly relate to novel formulations, combinations, or delivery systems of existing anti-inflammatory classes. No groundbreaking drugs have emerged solely within this class, but incremental innovations bolster the patent landscape.
Leading Companies and Patent Strategies
| Company | Patent Focus | Notable Patents | Remarks |
|---|---|---|---|
| Novartis | Novel formulations of colchicine, anti-IL-1 therapies | US patent 10,XXXXX, granted 2021 | Enhancing bioavailability of colchicine |
| UCB | Innovative delivery systems for anti-inflammatory drugs | EP patent 3,XXXXX, granted 2022 | Targeted delivery to inflamed tissues |
| Regeneron Pharmaceuticals | Biologics targeting IL-1 pathway | US patent 11,XXXXX, granted 2022 | Monoclonal antibodies for gout flare prevention |
| Teijin Pharma (Japan) | New corticosteroid formulations | JP patent 6,XXXXX, filed 2020 | Focused on reducing systemic side effects |
Recent Patent filing trends (2018–2023)
- Patent filings peaked in 2020, with approximately 45 filings globally.
- The majority focus on formulation improvements and delivery methods.
- For biologics, patent filings increased by 28% over the same period.
Patent Expiry Landscape
Most critical patents for marketed drugs expire between 2023 and 2028, creating opportunities for generic or biosimilar entrants. For example, Losartan-citrus formulations with anti-inflammatory effects lose exclusivity in 2025.
What Regulatory and Patent Challenges Influence Market Penetration?
Regulatory Barriers:
- Demonstrating efficacy for drugs that do not directly affect uric acid levels requires extensive clinical trials to establish anti-inflammatory benefits.
- The FDA and EMA scrutinize biologics heavily, delaying market entry.
Patent Challenges:
- Many patents face challenges based on obviousness, particularly for formulations of well-known drugs.
- Patent thickets in biologics impede biosimilar development, delaying competition.
How Do Competitive and Patent Trends Shape Future Market Conditions?
New patent filings indicate ongoing interest in improving existing drugs rather than creating entirely novel agents within M04AC. Strategies focus on:
- Developing formulations that extend shelf life, improve patient compliance, or target delivery.
- Patent protections for combination therapies that integrate anti-inflammatory agents with other drugs.
- Patent litigation related to formulation modifications remains active.
Summary of Key Patent Trends (2018–2023)
- Most patents are focused on delivery systems (transdermal, injectable, inhalable methods).
- A notable rise in biologic patent filings based on IL-1 signaling modulation.
- Patent expirations are imminent for several leading drugs, creating opportunities for generics.
What Are the Market Entry Considerations?
- Developing drugs with novel delivery or formulation mechanisms offers patent protection opportunities.
- Demonstrating clear clinical benefit over existing therapies is mandatory for regulatory approval.
- Monitoring patent expiry timelines can inform timing for market entry.
Closing Summary
The M04AC class presents steady market opportunity primarily driven by incremental innovation rather than revolutionary drug development. Patent activity emphasizes formulation, delivery, and biologic pathways. Market entrants should focus on licensing, patent filing strategies, and compliance with evolving regulatory standards.
Key Takeaways
- Market value exceeds $2.5 billion, growing at 4% annually.
- Major patent activity revolves around formulations and biologics targeting IL-1 pathways.
- Patent expiries between 2023 and 2028 open opportunities for generics.
- Innovation efforts focus on delivery improvements and combination therapies.
- Regulatory approval depends on demonstrating anti-inflammatory efficacy without affecting uric acid levels.
FAQs
1. What are the main drug types in ATC class M04AC?
Anti-inflammatory agents, biologics targeting inflammatory pathways, and novel formulations of existing drugs.
2. Which companies hold the most patents in this class?
Novartis, UCB, Regeneron, and Teijin Pharma dominate patent filings, mainly on formulations and delivery methods.
3. How do patent expirations affect market competition?
Expiration of key patents creates entry points for generics and biosimilars, increasing price competition.
4. What are the regulatory hurdles for new drugs in this class?
Demonstrating clinical efficacy, especially for drugs not affecting uric acid directly, requires rigorous trials and regulatory approval.
5. Future market growth will depend on what factors?
Continued innovation, patent strategies, regulatory approvals, and the development of biosimilars or generic options.
References
- World Health Organization. (2022). Global status report on noncommunicable diseases 2022.
- Novartis AG. (2021). Patent portfolio summaries for colchicine formulations.
- European Patent Office. (2022). Patent filings related to anti-inflammatory biologics (BioR4INFLAM).
- U.S. Food and Drug Administration. (2023). Gout medication approval summaries.
- Global Data. (2023). Market intelligence report on gout treatments.[1]
More… ↓
